Product Description
Frovatriptan is used to treat the symptoms of migraine headaches (severe throbbing headaches that sometimes are accompanied by nausea and sensitivity to sound and light). Frovatriptan is in a class of medications called selective serotonin receptor agonists. It works by narrowing blood vessels around the brain, blocking pain signals from being sent to the brain, and stopping the release of certain natural substances that cause pain, nausea, and other symptoms of migraine. (Sourced from: https://medlineplus.gov/druginfo/meds/a604013.html)
Mechanisms of Action: 5-HT1 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Belgium | Bulgaria | Canada | Chile | Colombia | Denmark | Dominican Republic | Egypt | Estonia | Finland | France | Germany | Greece | Hungary | Ireland | Italy | Korea | Latvia | Lithuania | Luxembourg | Netherlands | Peru | Portugal | Russia | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Tunisia | Turkey | Ukraine | United Kingdom | United States
Approved Indications: Cluster Headache | Migraine Disorders | Migraine with Aura | Migraine without Aura | Headache
Known Adverse Events: Chest Pain | Dizziness | Headache | Pain Unspecified | Paresthesia | Dyspepsia | Flushing | Common Cold
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|